While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...

Novavax Inc. closed $10.57 below its 52-week high ($23.86), which the company reached on June 6th.

Some people are making it their mission to get Novavax, rather than Pfizer or Moderna, for their COVID booster.

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.

In the most recent trading session, Novavax (NVAX) closed at $12.80, indicating a -0.85% shift from the previous trading day.

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.8 which represents a decrease of $-0.11 or -0.85% from the prior close of $12.91. The stock opened at $13.01 and touched a low ...

With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...

Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up.

The Food and Drug Administration (FDA) has authorized the emergency use of the Novavax COVID-19 Vaccine, Adjuvanted.

Health Canada authorized Novavax's updated COVID-19 vaccine that protects against currently circulating variants of the virus ...

Health Canada has approved an updated Novavax COVID-19 vaccine to protect against the variants of the virus currently ...